IDeA Clinical and Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional)
ID: 350041Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering the IDeA Clinical and Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional) to enhance biomedical research capacity in IDeA-eligible states. This funding opportunity aims to support the development of infrastructure and human resources for clinical and translational research, addressing health challenges faced by populations in these regions, and fostering collaboration among research institutions. Eligible organizations can apply for up to $3.3 million in annual direct costs over a maximum project period of five years, with applications accepted starting October 9, 2023, and closing on October 10, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the IDeA Clinical & Translational Research Network (CTR-N) Award (P50 Clinical Trial Optional). The funding opportunity primarily targets states with historically low NIH funding success rates to enhance biomedical research capacity and support clinical research addressing health challenges in these populations. Eligible organizations, particularly in IDeA-eligible states, can submit one application for up to $3.3 million in annual direct costs over a maximum project period of five years. The CTR-N must be directed by a health research organization with proven clinical research capabilities and include a statewide or multi-state network of partner organizations. The application should feature essential components, including Administrative, Research Design, Community Engagement, Professional Development, and Health Research Cores, which collectively promote collaborative research and workforce development. Additionally, applicants are required to submit a Plan for Enhancing Diverse Perspectives (PEDP) to illustrate strategies for fostering inclusivity in research activities. The application can be submitted via the NIH ASSIST system or through an institutional system-to-system solution. Key dates include an open application date starting October 9, 2023, with the opportunity expiring on October 10, 2025.
    Similar Opportunities
    IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional) to enhance clinical and translational research capabilities in IDeA-eligible states. This funding opportunity aims to strengthen workforce development and improve infrastructure in health research organizations that typically have limited capacities for such research, with a focus on building research capacity and fostering collaboration within the community. Each organization can submit one application with a budget not exceeding $1.5 million over a maximum project period of five years, and successful applicants must address various cores including Administrative, Professional Development, Community Engagement, Research Design/Compliance, and Health Research, while also emphasizing diversity and inclusion in research. Interested applicants can find more information and submit their applications through the NIH ASSIST system or Grants.gov, with the application deadline set for October 9, 2025.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Funding Opportunity titled "High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development of unique capabilities and resources to address critical gaps in clinical and translational science within awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs. The funding opportunity, numbered PAR-25-156, allows for project budgets of up to $500,000 per year over a project period of up to five years, with applications involving clinical trials being optional. Interested applicants, primarily from public and state-controlled institutions of higher education, must submit detailed integration plans, milestones, and sustainability evaluations by the closing date of September 28, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Clinical and Translational Science Award (CTSA) Program, aimed at enhancing clinical and translational research through collaborative partnerships. This initiative invites applications for hubs that will focus on improving the efficiency of clinical translation, addressing health disparities, and fostering innovative research methodologies, with a particular emphasis on community engagement and workforce development. Successful applicants, which may include higher education institutions and nonprofit organizations, are expected to outline strategic management and demonstrate strong leadership, with projects capped at seven years and a submission deadline of September 28, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the funding opportunity page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-272.html.
    Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) for the Clinical and Translational Science Award (CTSA) Program, specifically the Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). This funding opportunity aims to foster meaningful collaborations and innovative projects in clinical and translational science, with no cost-sharing or matching requirements for eligible applicants, which include for-profit organizations. The estimated total program funding is $5 million, with an award ceiling of $650,000, and the NOFO is expected to be published in Fall 2024, with applications due in Winter 2025. Interested parties should prepare for the anticipated timeline, as the estimated project start date is December 1, 2025, and further details can be found on the CCIA webpage.
    Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition funding opportunity titled the Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3), aimed at enhancing translational research through collaborative efforts among multiple medical research institutions. This initiative seeks to support the development, implementation, and dissemination of innovative solutions that address urgent public health needs and promote health equity, requiring applicants to include at least three eligible organizations to foster interdisciplinary partnerships. Eligible projects can receive funding of up to $650,000 annually for a total duration of up to five years, with applications due by October 19, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-296.html.
    Notice of Intent to Publish a Notice of Funding Opportunity for the Re-Issue of PAR-21-293 - Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to reissue a Notice of Funding Opportunity (NOFO) for the Clinical and Translational Science Award (CTSA) Program, aimed at establishing hubs that will contribute to a national consortium focused on accelerating the delivery of treatments to patients through advancements in clinical and translational science. This initiative is designed to foster meaningful collaborations and responsive projects among eligible applicants, which include various organizations and institutions. The anticipated NOFO is expected to be published in Summer 2024, with applications due by January 2025, and the estimated award date is set for December 16, 2025. Interested parties should prepare for the upcoming application process as no cost-sharing or matching is required for this cooperative agreement funding opportunity.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development and demonstration of innovative resources and capabilities within Clinical and Translational Science Awards (CTSA) Program hubs, specifically targeting critical gaps and roadblocks in clinical research. Successful applicants, who must be active UM1 CTSA award recipients, will propose projects lasting up to five years with an annual budget cap of $500,000, emphasizing collaboration and innovation in health research. Interested parties should note that the application deadline is September 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    IDeA Networks of Biomedical Research Excellence (INBRE) (P20 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) program, aimed at enhancing the biomedical research capacity in IDeA-eligible states. This grant opportunity supports statewide networks of higher education and research institutions to foster faculty research, mentoring, and student involvement, with a focus on developing institutional infrastructure. The program allows for a maximum annual budget of $2.75 million over five years, requiring each application to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. Interested applicants can find more information and submit proposals by the closing date of May 22, 2025, and should direct inquiries to grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.